Titre : Phosphatidylinositol-4-phosphate 3-kinase

Phosphatidylinositol-4-phosphate 3-kinase : Questions médicales fréquentes

Termes MeSH sélectionnés :

Image Interpretation, Computer-Assisted
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Phosphatidylinositol-4-phosphate 3-kinase : Questions médicales les plus fréquentes", "headline": "Phosphatidylinositol-4-phosphate 3-kinase : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Phosphatidylinositol-4-phosphate 3-kinase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-02", "dateModified": "2025-02-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Phosphatidylinositol-4-phosphate 3-kinase" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Phosphatidylinositol 3-kinases", "url": "https://questionsmedicales.fr/mesh/D019869", "about": { "@type": "MedicalCondition", "name": "Phosphatidylinositol 3-kinases", "code": { "@type": "MedicalCode", "code": "D019869", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.556" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Phosphatidylinositol 3-kinases de classe I", "alternateName": "Class I Phosphatidylinositol 3-Kinases", "url": "https://questionsmedicales.fr/mesh/D058534", "about": { "@type": "MedicalCondition", "name": "Phosphatidylinositol 3-kinases de classe I", "code": { "@type": "MedicalCode", "code": "D058534", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.556.200.100" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Phosphatidylinositol 3-kinase de classe Ia", "alternateName": "Class Ia Phosphatidylinositol 3-Kinase", "url": "https://questionsmedicales.fr/mesh/D058543", "about": { "@type": "MedicalCondition", "name": "Phosphatidylinositol 3-kinase de classe Ia", "code": { "@type": "MedicalCode", "code": "D058543", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.556.200.100.100" } } }, { "@type": "MedicalWebPage", "name": "Phosphatidylinositol 3-kinases de classe Ib", "alternateName": "Class Ib Phosphatidylinositol 3-Kinase", "url": "https://questionsmedicales.fr/mesh/D058544", "about": { "@type": "MedicalCondition", "name": "Phosphatidylinositol 3-kinases de classe Ib", "code": { "@type": "MedicalCode", "code": "D058544", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.556.200.100.200" } } } ] }, { "@type": "MedicalWebPage", "name": "Phosphatidylinositol 3-kinases de classe II", "alternateName": "Class II Phosphatidylinositol 3-Kinases", "url": "https://questionsmedicales.fr/mesh/D058541", "about": { "@type": "MedicalCondition", "name": "Phosphatidylinositol 3-kinases de classe II", "code": { "@type": "MedicalCode", "code": "D058541", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.556.200.200" } } } ], "about": { "@type": "MedicalCondition", "name": "Phosphatidylinositol-4-phosphate 3-kinase", "alternateName": "Phosphatidylinositol-4-Phosphate 3-Kinase", "code": { "@type": "MedicalCode", "code": "D058538", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Padinjat Raghu", "url": "https://questionsmedicales.fr/author/Padinjat%20Raghu", "affiliation": { "@type": "Organization", "name": "Cellular Organization and Signaling, National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore, 560065, India. Electronic address: praghu@ncbs.res.in." } }, { "@type": "Person", "name": "Swarna Mathre", "url": "https://questionsmedicales.fr/author/Swarna%20Mathre", "affiliation": { "@type": "Organization", "name": "National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India; Manipal Academy of Higher Education, Manipal, Karnataka 576104, India." } }, { "@type": "Person", "name": "Mariko Kato", "url": "https://questionsmedicales.fr/author/Mariko%20Kato", "affiliation": { "@type": "Organization", "name": "Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan." } }, { "@type": "Person", "name": "Tomohiko Tsuge", "url": "https://questionsmedicales.fr/author/Tomohiko%20Tsuge", "affiliation": { "@type": "Organization", "name": "Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan." } }, { "@type": "Person", "name": "Takashi Aoyama", "url": "https://questionsmedicales.fr/author/Takashi%20Aoyama", "affiliation": { "@type": "Organization", "name": "Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Computational modeling and druggability assessment of Aggregatibacter actinomycetemcomitans leukotoxin.", "datePublished": "2022-06-13", "url": "https://questionsmedicales.fr/article/35724475", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cmpb.2022.106952" } }, { "@type": "ScholarlyArticle", "name": "The Application of a Computer Monitoring System Using IoT Technology.", "datePublished": "2022-06-06", "url": "https://questionsmedicales.fr/article/35707190", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1155/2022/4033886" } }, { "@type": "ScholarlyArticle", "name": "Diagnostic Utility of Computed Tomography Perfusion in the Telestroke Setting.", "datePublished": "2022-06-02", "url": "https://questionsmedicales.fr/article/35652343", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1161/STROKEAHA.122.038798" } }, { "@type": "ScholarlyArticle", "name": "Persistent trigeminal artery detected on computed tomography angiography.", "datePublished": "2022-05-23", "url": "https://questionsmedicales.fr/article/35604462", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00276-022-02960-5" } }, { "@type": "ScholarlyArticle", "name": "Flexibility in valenced reinforcement learning computations across development.", "datePublished": "2022-05-21", "url": "https://questionsmedicales.fr/article/35596654", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/cdev.13791" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Phosphatidylinositol 3-kinases", "item": "https://questionsmedicales.fr/mesh/D019869" }, { "@type": "ListItem", "position": 6, "name": "Phosphatidylinositol-4-phosphate 3-kinase", "item": "https://questionsmedicales.fr/mesh/D058538" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Phosphatidylinositol-4-phosphate 3-kinase - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Phosphatidylinositol-4-phosphate 3-kinase", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Phosphatidylinositol-4-phosphate 3-kinase", "description": "Comment diagnostiquer une dysfonction de PI3K ?\nQuels tests sont utilisés pour évaluer PI3K ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème avec PI3K ?\nY a-t-il des marqueurs spécifiques pour PI3K ?", "url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Image+Interpretation,+Computer-Assisted&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Phosphatidylinositol-4-phosphate 3-kinase", "description": "Quels sont les symptômes d'une activation anormale de PI3K ?\nComment PI3K affecte-t-il le métabolisme ?\nLes troubles neurologiques sont-ils liés à PI3K ?\nY a-t-il des signes cutanés associés à PI3K ?\nLes douleurs articulaires peuvent-elles être liées à PI3K ?", "url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Image+Interpretation,+Computer-Assisted&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Phosphatidylinositol-4-phosphate 3-kinase", "description": "Peut-on prévenir les troubles liés à PI3K ?\nY a-t-il des tests de dépistage pour PI3K ?\nLes habitudes alimentaires influencent-elles PI3K ?\nL'exercice physique aide-t-il à réguler PI3K ?\nLes facteurs environnementaux affectent-ils PI3K ?", "url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Image+Interpretation,+Computer-Assisted&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Phosphatidylinositol-4-phosphate 3-kinase", "description": "Quels traitements ciblent PI3K ?\nLes thérapies géniques peuvent-elles aider ?\nY a-t-il des effets secondaires des inhibiteurs de PI3K ?\nComment la nutrition influence-t-elle PI3K ?\nLes traitements sont-ils personnalisés pour PI3K ?", "url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Image+Interpretation,+Computer-Assisted&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Phosphatidylinositol-4-phosphate 3-kinase", "description": "Quelles complications peuvent survenir avec PI3K ?\nLes maladies cardiovasculaires sont-elles liées à PI3K ?\nComment PI3K influence-t-il le cancer ?\nY a-t-il des risques de résistance aux traitements ?\nLes troubles métaboliques sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Image+Interpretation,+Computer-Assisted&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Phosphatidylinositol-4-phosphate 3-kinase", "description": "Quels sont les facteurs de risque pour les troubles de PI3K ?\nL'âge influence-t-il le risque lié à PI3K ?\nLe stress a-t-il un impact sur PI3K ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'alimentation influence-t-elle le risque de troubles de PI3K ?", "url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Image+Interpretation,+Computer-Assisted&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction de PI3K ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses biochimiques peuvent être utilisés pour diagnostiquer les anomalies de PI3K." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer PI3K ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests d'activité enzymatique et les dosages de métabolites spécifiques sont courants." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des biopsies peuvent être nécessaires pour évaluer l'expression de PI3K dans les tissus." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec PI3K ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes variés comme des troubles métaboliques ou des anomalies de croissance peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour PI3K ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs moléculaires comme PIK3CA peuvent indiquer une activation anormale de PI3K." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une activation anormale de PI3K ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des troubles métaboliques, des anomalies de croissance et des cancers." } }, { "@type": "Question", "name": "Comment PI3K affecte-t-il le métabolisme ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "PI3K régule le métabolisme en influençant la signalisation de l'insuline et la lipogenèse." } }, { "@type": "Question", "name": "Les troubles neurologiques sont-ils liés à PI3K ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dysfonctionnements de PI3K peuvent être associés à des troubles neurologiques." } }, { "@type": "Question", "name": "Y a-t-il des signes cutanés associés à PI3K ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies cutanées peuvent apparaître, notamment dans des syndromes génétiques liés à PI3K." } }, { "@type": "Question", "name": "Les douleurs articulaires peuvent-elles être liées à PI3K ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles inflammatoires peuvent être exacerbés par des anomalies de PI3K." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles liés à PI3K ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation saine et un mode de vie actif peuvent réduire les risques associés à PI3K." } }, { "@type": "Question", "name": "Y a-t-il des tests de dépistage pour PI3K ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent être recommandés pour les personnes à risque de troubles liés à PI3K." } }, { "@type": "Question", "name": "Les habitudes alimentaires influencent-elles PI3K ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en acides gras oméga-3 peut moduler l'activité de PI3K." } }, { "@type": "Question", "name": "L'exercice physique aide-t-il à réguler PI3K ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la signalisation de PI3K et la santé métabolique." } }, { "@type": "Question", "name": "Les facteurs environnementaux affectent-ils PI3K ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains toxiques peut influencer l'activité de PI3K et le risque de maladies." } }, { "@type": "Question", "name": "Quels traitements ciblent PI3K ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de PI3K sont utilisés dans le traitement de certains cancers et maladies métaboliques." } }, { "@type": "Question", "name": "Les thérapies géniques peuvent-elles aider ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie génique peut corriger des mutations dans les gènes codant pour PI3K." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des inhibiteurs de PI3K ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des troubles gastro-intestinaux et des infections." } }, { "@type": "Question", "name": "Comment la nutrition influence-t-elle PI3K ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut moduler l'activité de PI3K et améliorer la santé métabolique." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés pour PI3K ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques de PI3K." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec PI3K ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des cancers, des troubles métaboliques et des maladies cardiovasculaires." } }, { "@type": "Question", "name": "Les maladies cardiovasculaires sont-elles liées à PI3K ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies de PI3K peuvent contribuer à des maladies cardiovasculaires par des mécanismes inflammatoires." } }, { "@type": "Question", "name": "Comment PI3K influence-t-il le cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "PI3K est souvent activé dans divers cancers, favorisant la croissance tumorale et la survie cellulaire." } }, { "@type": "Question", "name": "Y a-t-il des risques de résistance aux traitements ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des mutations dans PI3K peuvent entraîner une résistance aux inhibiteurs de PI3K." } }, { "@type": "Question", "name": "Les troubles métaboliques sont-ils réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certains troubles métaboliques liés à PI3K peuvent être gérés par des changements de mode de vie." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les troubles de PI3K ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des prédispositions génétiques, l'obésité et un mode de vie sédentaire." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque lié à PI3K ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de troubles liés à PI3K augmente avec l'âge en raison de l'accumulation de mutations." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur PI3K ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affecter la signalisation de PI3K et contribuer à des maladies." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancers ou de troubles métaboliques augmentent le risque." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le risque de troubles de PI3K ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en sucres et graisses saturées peut augmenter le risque." } } ] } ] }

Sources (10000 au total)

Diagnostic Utility of Computed Tomography Perfusion in the Telestroke Setting.

Definitive diagnosis of acute ischemic stroke is challenging, particularly in telestroke settings. Although the prognostic utility of CT perfusion (CTP) has been questioned, its diagnostic value remai... Acute and follow-up data collected prospectively from consecutive suspected patients with stroke assessed by a state-wide telestroke service between March 2020 and August 2021 at 12 sites in Australia... During the study period, complete multimodal CT examination was obtained in 831 patients, 457 of whom were diagnosed with stroke. Diagnostic sensitivity for ischemic stroke increased by 19.5 percentag... Acquisition of CTP as part of a telestroke imaging protocol permits definitive diagnosis of cerebral ischemia in 1 in 5 patients with normal NCCT and CTA....

Persistent trigeminal artery detected on computed tomography angiography.

This study aimed to investigate the prevalence of persistent trigeminal arteries (PTAs) using computed tomography (CT) angiography, emphasize its major characteristics, and compare the findings with t... Patients who underwent cerebral CT angiography in our radiology clinic for any preliminary diagnosis between December 2013 and December 2020 were included in this retrospective study. The patients wer... A total of 1150 patients, (632 [55%] males and 518 [45%] females) were included in this study. A total of seven (0.6%) patients had PTAs. PTAs were located on the right and left sides in three (43%) a... In conclusion, understanding the diagnosis and classification of PTAs is crucial for the diagnosis of possible vascular pathologies by neuroradiologists and physicians performing neurovascular interve...

The role of surveillance computed tomography in patients with follicular lymphoma.

Surveillance computed tomography (CT) is performed during the follow-up of patients with lymphoma who have completed initial therapy. However, studies on the clinical benefit of surveillance CT for pa... We retrospectively reviewed the medical records of patients with FL who achieved CR with first-line treatment between 2000 and 2016 at our institution. In patients who experienced first relapse, we ex... Of the 248 patients who achieved CR after initial therapy, 109 had a relapse, with a median follow-up of 11 years; 100 were enrolled into this study. Relapse was detected by surveillance CT in 61 pati... Surveillance CT did not show any clinical benefit for patients with FL in CR; however, it might lead to early detection of relapse in cases of deep lesions that cannot be identified without imaging....

Toward subtalar joint axis-driven computer-aided design and computer-aided manufacturing foot orthoses: Reliability of a noninvasive clinical scanning protocol.

The subtalar joint axis (STJA) occupies a key role in the dynamics of the lower limb kinetic chain, and its location has a wide interindividual variability. It has been suggested that considering the ... This study aimed to evaluate the reliability of the STJA digitization, a procedure combining the clinical determination of the functional STJA location and its subsequent 3-dimensional (3D) scanning.... Two examiners identified the posterior and anterior exit points of the functional STJA on the skin of 15 healthy participants using a clinical method in a repeated-measure design.... A handheld 3D scanner was used to scan the feet and the skin markers. The 3D coordinates of the skin markers were subsequently quantified and (1) STJA digitization intratester within-session, (2) STJA... When pooling all skin marker 3D coordinates, intraclass correlation coefficients (ICCs) for the STJA intratester within-session reliability ranged from 0.74 to 0.98. ICCs for the STJA digitization int... Overall, the STJA digitization demonstrated a good intratester between-session reliability and may be used in a computer-aided design and computer-aided manufacturing workflow to create foot orthoses....

Iodine contrast volume reduction in preoperative transcatheter aortic valve implantation computed tomography: Comparison with 64- and 256-multidetector row computed tomography.

This study aimed to compare the vascular enhancement and radiation dose in preoperative transcatheter aortic valve implantation (TAVI) computed tomography (CT) with a reduced contrast medium (CM) usin... This study included 78 patients with preoperative TAVI CT with either 64- or 256-MDCT. The CM was injected at 1.5 mL/kg in the 64-MDCT group and 1.0 mL/kg in the 256-MDCT group. We compared vascular e... Despite the reduced CM (by 33 %) in the 256-MDCT group, the mean vascular enhancement of the right and left subclavian arteries was significantly higher than that in the 64-MDCT group [284 and 267 Hou... In preoperative TAVI CT, volume scans using 256-MDCT provide comparable or better vascular enhancement and IQ with a 30 % reduction in CM and radiation dose than those using 64-MDCT.... Volume scan using 256-MDCT for preoperative TAVI CT may reduce CM and radiation dose in TAVI patients with renal dysfunction....